BIOMAT Database Logo BIOMAT Database Logo

Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis. 1998

S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Second Department of Surgery, Hiroshima University School of Medicine, Japan.

Post-transplant erythrocytosis (PTE) is increasingly recognized as a complication of kidney transplantation. In this study we report the effect of the angiotesin-converting enzyme (ACE) inhibitor enalapril on hematocrit (Ht) and erythropoietin in four patients with PTE. Four renal allograft recipients with Ht greater than 51% were studied. Treatment was initiated with enalapril administered orally at a dose of 2.5 mg/day. All the patients had an increase of hemoglobin (Hb) (17.7 +/- 0.64 g/dl), Ht (54.5 +/- 1.29%) and red blood cell count (RBC) (584 +/- 19.2 x 10(4)/microliter). All patients responded to enalapril in 8 weeks with a significant decrease of Hb, Ht, and RBC. In one patient, the downward trend was more rapid and sustained, and treatment had to be discontinued to prevent the development of anemia. Serum erythropoietin showed normal in all four patients and remained unchanged during the study, even after discontinuation of enalapril treatment. Serum creatinine remained relatively stable throughout the study. These results suggest that PTE may not be dependent upon circulating erythropoietin and that enalapril treatment may be an effective treatment of PTE without renal dysfunction.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011086 Polycythemia An increase in the total red cell mass of the blood. (Dorland, 27th ed) Erythrocytosis,Erythrocytoses,Polycythemias
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal

Related Publications

S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Angiotensin converting enzyme gene polymorphism and development of post-transplant erythrocytosis.
January 2003, Journal of nephrology,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Enalapril: a new angiotensin-converting enzyme inhibitor.
October 1986, Iowa medicine : journal of the Iowa Medical Society,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Enalapril: a new angiotensin converting enzyme inhibitor.
March 1986, Drug intelligence & clinical pharmacy,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
January 1985, Clinical pharmacy,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Clinical pharmacology of the angiotensin converting enzyme inhibitor, enalapril.
January 1986, Acta cardiologica,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Enalapril: a long-acting angiotensin-converting enzyme inhibitor.
January 1987, Pharmacotherapy,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Enalapril: a second-generation angiotensin converting enzyme inhibitor.
November 1988, The American journal of the medical sciences,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition.
January 1995, American journal of nephrology,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients.
June 1995, Nihon Jinzo Gakkai shi,
S Marubayashi, and H Yamamoto, and S Shibata, and Y Fudaba, and Y Miyata, and K Fukuma, and K Okada, and T Hinoi, and M Ikeda, and T Maeda, and Y Oshiro, and K Dohi
Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats.
January 1996, Polish journal of pharmacology,
Copied contents to your clipboard!